| ACC | American College of Cardiology |
| ACE | angiotensin I-converting enzyme |
| ACS | acute coronary syndrome |
| ADP | P2Y12 receptor: adenosine 5′diphosphate P2Y12 receptor |
| AHA | American Heart Association |
| APTT | activated partial thromboplastin time |
| aPL | antiphospholipid |
| APS | antiphospholipid syndrome |
| ARDS | acute respiratory distress syndrome |
| CAD | coronary artery disease |
| Cit-H3 | citrullinated histone H3 |
| CTC | cardiac thrombotic complication |
| CVD | cardiovascular disease |
| COVID-19 | coronavirus disease 2019 |
| CYP3A4 | cytochrome P450 3A4 |
| CYP2C19 | Cytochrome P450 2C19 |
| CRP | C-reactive protein |
| DIC | disseminated intravascular coagulation |
| DILI | drug-induced liver injury |
| dsDNA | double-stranded DNA |
| ESC | European Society of Cardiology |
| ICU | intensive care unit |
| IL | interleukine |
| INR | international normalized ratio |
| MI | myocardial infarction |
| MPO-DNA | myeloperoxidase-DNA |
| NADPH | nicotinamide adenine dinucleotide phosphate |
| NETs | neutrophil extracellular traps. |
| PAI-1 | plasminogen activator inhibitor 1 |
| PCI | percutaneous coronary intervention |
| PE | pulmonary embolism |
| PT | prothrombin time |
| RAAS | renin-angiotensin-aldosterone system |
| RUCAM | Roussel Uclaf Causality Assessment Method |
| SARS-CoV-2 | severe acute respiratory syndrome-coronavirus-2 |
| SIRS | systemic inflammatory response syndrome |
| STEMI | ST elevation myocardial infarction |
| TED | thromboembolic disease |
| TNF | tumor necrosis factor |
| TT | thrombin time |